Abstract
Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series of hybrid small compounds, called SNIPERs (Specific and Nongenetic IAP-dependent Protein ERasers); and peptidic chimeric molecules, called PROTACs (proteolysis-targeting chimeric molecules), which induce selective degradation of target proteins via the ubiquitin-proteasome pathway. These compounds include two different ligands connected by a linker; one is a ligand for a ubiquitin ligase and the other is a ligand for the target protein, which are expected to crosslink these proteins in cells. Theoretically, any cytosolic protein can be targeted for degradation by this technology. To date, several SNIPERs and PROTACs against various oncogenic proteins have been developed, which specifically induce polyubiquitylation and proteasomal degradation of the oncogenic proteins, resulting in cell death, growth arrest, or impaired migration of cancer cells. Thus, this protein knockdown technology has a great potential for cancer therapy.
Keywords: IAP, PROTAC (proteolysis-targeting chimeric molecule), proteasome, protein knockdown, SNIPER (Specific and Nongenetic IAP-dependent Protein ERasers), ubiquitin ligase.
Current Cancer Drug Targets
Title:Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Volume: 16 Issue: 2
Author(s): Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito
Affiliation:
Keywords: IAP, PROTAC (proteolysis-targeting chimeric molecule), proteasome, protein knockdown, SNIPER (Specific and Nongenetic IAP-dependent Protein ERasers), ubiquitin ligase.
Abstract: Selective degradation of pathogenic proteins by small molecules in cells is a novel approach for development of therapeutic agents against various diseases, including cancer. We and others have developed a protein knockdown technology with a series of hybrid small compounds, called SNIPERs (Specific and Nongenetic IAP-dependent Protein ERasers); and peptidic chimeric molecules, called PROTACs (proteolysis-targeting chimeric molecules), which induce selective degradation of target proteins via the ubiquitin-proteasome pathway. These compounds include two different ligands connected by a linker; one is a ligand for a ubiquitin ligase and the other is a ligand for the target protein, which are expected to crosslink these proteins in cells. Theoretically, any cytosolic protein can be targeted for degradation by this technology. To date, several SNIPERs and PROTACs against various oncogenic proteins have been developed, which specifically induce polyubiquitylation and proteasomal degradation of the oncogenic proteins, resulting in cell death, growth arrest, or impaired migration of cancer cells. Thus, this protein knockdown technology has a great potential for cancer therapy.
Export Options
About this article
Cite this article as:
Ohoka Nobumichi, Shibata Norihito, Hattori Takayuki and Naito Mikihiko, Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009616666151112122502
DOI https://dx.doi.org/10.2174/1568009616666151112122502 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry In Vitro, In Vivo and In Silico Analysis of the Anticancer and Estrogen-like Activity of Guava Leaf Extracts
Current Medicinal Chemistry Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Transcriptomics of Antipsychotic Drug Function: What have we Learned from Rodent Studies?
Current Psychopharmacology Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Current Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
Anti-Cancer Agents in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity
Current Pharmaceutical Design Amphiphilic Cyclodextrin Derivatives for Targeted Drug Delivery to Tumors
Current Topics in Medicinal Chemistry SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Current Cancer Drug Targets Cross Talks Between Oncoprotein Signaling Networks and Tumor Suppressor p53 in Breast Cancer
Current Cancer Therapy Reviews Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews